- Home
- ACLX vs PRCT Comparison
ACLX vs PRCT Comparison
Compare ACLX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- PRCT
- Stock Information
- Founded
- ACLX 2015
- PRCT 2009
- Country
- ACLX United States
- PRCT United States
- Employees
- ACLX N/A
- PRCT N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- ACLX Health Care
- PRCT Health Care
- Exchange
- ACLX Nasdaq
- PRCT Nasdaq
- Market Cap
- ACLX 5.3B
- PRCT 5.3B
- IPO Year
- ACLX 2022
- PRCT 2021
- Fundamental
- Price
- ACLX $78.90
- PRCT $84.93
- Analyst Decision
- ACLX Strong Buy
- PRCT Strong Buy
- Analyst Count
- ACLX 14
- PRCT 7
- Target Price
- ACLX $107.67
- PRCT $97.86
- AVG Volume (30 Days)
- ACLX 599.1K
- PRCT 573.6K
- Earning Date
- ACLX 11-07-2024
- PRCT 10-28-2024
- Dividend Yield
- ACLX N/A
- PRCT N/A
- EPS Growth
- ACLX N/A
- PRCT N/A
- EPS
- ACLX N/A
- PRCT N/A
- Revenue
- ACLX $155,818,000.00
- PRCT $199,843,000.00
- Revenue This Year
- ACLX $12.58
- PRCT $67.07
- Revenue Next Year
- ACLX N/A
- PRCT $40.64
- P/E Ratio
- ACLX N/A
- PRCT N/A
- Revenue Growth
- ACLX 230.33
- PRCT 71.71
- 52 Week Low
- ACLX $47.88
- PRCT $39.48
- 52 Week High
- ACLX $107.37
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- ACLX 40.06
- PRCT 39.80
- Support Level
- ACLX $73.39
- PRCT $79.30
- Resistance Level
- ACLX $90.23
- PRCT $92.92
- Average True Range (ATR)
- ACLX 4.31
- PRCT 3.50
- MACD
- ACLX -0.60
- PRCT -1.21
- Stochastic Oscillator
- ACLX 27.75
- PRCT 22.87
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.